Chemistry:Remibrutinib

From HandWiki

Remibrutinib, sold under the brand name Rhapsido, is a medication used for the treatment of chronic spontaneous urticaria.[1] Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton's tyrosine kinase.[1] It is taken by mouth.[1]

Remibrutinib was approved for medical use in the United States in September 2025,[2] and in the European Union in April 2026.[3][4] The US Food and Drug Administration considers it to be a first-in-class medication.[5][6]

Medical uses

Remibrutinib is indicated for the treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment.[1][3]

Side effects

Common side effects include upper respiratory tract infections, headache, nasopharyngitis, and mild gastrointestinal symptoms such as diarrhea and nausea.[7][8]

Mechanism of action

Remibrutinib is a selective inhibitor of Bruton's tyrosine kinase, a key signaling protein found in mast cells and basophils that regulates their activation and degranulation via pathways involving the FcεRI and B-cell receptor. By irreversibly binding to Bruton's tyrosine kinase, remibrutinib blocks intracellular signaling required for the release of histamine and other inflammatory mediators, thereby reducing the immune cell-driven processes underlying chronic spontaneous urticaria. This mechanism enables suppression of urticaria symptoms upstream from antihistamines, and may also modulate autoimmune activity in some patients.[8]

Society and culture

Remibrutinib was approved for medical use in the United States in September 2025.[9]

Names

Remibrutinib is the international nonproprietary name.[10]

Remibrutinib is sold under the brand name Rhapsido.[9]

References

  1. ↑ 1.0 1.1 1.2 1.3 Cite error: Invalid <ref> tag; no text was provided for refs named Rhapsido FDA label
  2. ↑ "Drug Approval Package: Rhapsido". 6 November 2025. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218436Orig1s000TOC.html. 
  3. ↑ 3.0 3.1 Cite error: Invalid <ref> tag; no text was provided for refs named Rhapsido EPAR
  4. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named Rhapsido PI
  5. ↑ "Novel Drug Approvals for 2025". 8 July 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025. 
  6. ↑ "Advancing Health Through Innovation: New Drug Therapy Approvals 2025" (PDF). January 2026. https://www.fda.gov/media/190705/download. 
  7. ↑ "Safety and Efficacy of Remibrutinib for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis". International Archives of Allergy and Immunology: 1–12. September 2025. doi:10.1159/000548302. PMID 40911497. 
  8. ↑ 8.0 8.1 "Evaluating remibrutinib in the treatment of chronic spontaneous urticaria". Immunotherapy 17 (7): 479–484. May 2025. doi:10.1080/1750743X.2025.2510892. PMID 40455080. 
  9. ↑ 9.0 9.1 "Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)" (Press release). Novartis Pharmaceuticals. 30 September 2025. Retrieved 1 October 2025 – via PR Newswire.
  10. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information 34 (1). 2020. 

Further reading

  • Maurer, Marcus; Berger, William; Giménez-Arnau, Ana; Hayama, Koremasa; Jain, Vipul; Reich, Adam; Haemmerle, Sibylle; Lheritier, Karine et al. (December 2022). "Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria". The Journal of Allergy and Clinical Immunology 150 (6): 1498–1506.e2. doi:10.1016/j.jaci.2022.08.027. ISSN 1097-6825. PMID 36096203. 
  • Maurer, Marcus; Giménez-Arnau, Ana; Jain, Vipul; Tillinghast, Jeffrey; Tolcachier, Alberto; Nigen, Simon; Hayam, Koremasa; Lheritier, Karine et al. (February 2022). "Remibrutinib Treatment Improves Quality of Life in Patients with Chronic Spontaneous Urticaria". Journal of Allergy and Clinical Immunology 149 (2): AB179. doi:10.1016/j.jaci.2021.12.589. 
  • Clinical trial number NCT05030311 for "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)" at ClinicalTrials.gov
  • Clinical trial number NCT05032157 for "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines (REMIX-2)" at ClinicalTrials.gov